Department of Pharmacy, Taizhou Municipal Hospital, Taizhou, 318000, People's Republic of China.
College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Int J Nanomedicine. 2021 Jun 17;16:4147-4159. doi: 10.2147/IJN.S303829. eCollection 2021.
To develop microchannel-based preparation of curcumin (Cur)-loaded hybrid nanoparticles using enzyme-targeted peptides and star-shaped polycyclic lipids as carriers, and to accomplish a desirable targeted drug delivery via these nanoparticles, which could improve the bioavailability and antitumor effects of Cur.
The amphiphilic tri-chaintricarballylic acid-poly (ε-caprolactone)-methoxypolyethylene glycol (Tri-CL-mPEG) and the enzyme-targeted tetra-chain pentaerythritol-poly (ε-caprolactone)-polypeptide (PET-CL-P) were synthesized. The Cur-loaded enzyme-targeted hybrid nano-delivery systems (Cur-P-NPs) were prepared by using the microfluidic continuous granulation technology. The physicochemical properties, release behavior in vitro, and stability of these Cur-P-NPs were investigated. Their cytotoxicity, cellular uptake, anti-proliferative efficacy in vitro, biodistribution, and antitumor effects in vivo were also studied.
The particle size of the prepared Cur-P-NPs was 146.1 ± 1.940 nm, polydispersity index was 0.175 ± 0.014, zeta potential was 10.1 ± 0.300 mV, encapsulation rate was 74.66 ± 0.671%, and drug loading capacity was 5.38 ± 0.316%. The stability of Cur-P-NPs was adequate, and the in vitro release rate increased with the decrease of the environmental pH. Seven days post incubation, the cumulative release values of Cur were 52.78%, 67.39%, and 98.12% at pH 7.4, pH 6.8 and pH 5.0, respectively. Cur-P-NPs exhibited better cell entry and antiproliferation efficacy against U251 cells than the Cur-solution and Cur-NPs and were safe for use. Cur-P-NPs specifically targeted tumor tissues and inhibited their growth (78.63% tumor growth inhibition rate) with low toxic effects on normal tissues.
The enzyme-targeted hybrid nanoparticles prepared in the study clearly have the tumor-targeting ability. Cur-P-NPs can effectively improve the bioavailability of Cur and have potential applications in drug delivery and tumor management.
开发基于微通道的姜黄素(Cur)负载杂化纳米粒子,使用酶靶向肽和星形多环脂质作为载体,并通过这些纳米粒子实现理想的靶向药物递送,从而提高 Cur 的生物利用度和抗肿瘤效果。
合成两亲性三链三羧酸-聚(ε-己内酯)-甲氧基聚乙二醇(Tri-CL-mPEG)和酶靶向四链五赤藻糖醇-聚(ε-己内酯)-多肽(PET-CL-P)。采用微流控连续造粒技术制备载酶靶向杂化纳米递药系统(Cur-P-NPs)。考察了这些 Cur-P-NPs 的理化性质、体外释放行为和稳定性。还研究了它们的细胞毒性、细胞摄取、体外抗增殖作用、体内分布和体内抗肿瘤作用。
制备的 Cur-P-NPs 的粒径为 146.1 ± 1.940nm,多分散指数为 0.175 ± 0.014,Zeta 电位为 10.1 ± 0.300mV,包封率为 74.66 ± 0.671%,载药量为 5.38 ± 0.316%。Cur-P-NPs 的稳定性足够,体外释放率随环境 pH 值的降低而增加。孵育 7 天后,在 pH7.4、pH6.8 和 pH5.0 下,Cur 的累积释放值分别为 52.78%、67.39%和 98.12%。Cur-P-NPs 对 U251 细胞的细胞进入和抗增殖作用优于 Cur 溶液和 Cur-NPs,且使用安全。Cur-P-NPs 对肿瘤组织具有特异性靶向能力,并抑制其生长(78.63%的肿瘤生长抑制率),对正常组织的毒性作用较低。
研究中制备的酶靶向杂化纳米粒子具有明显的肿瘤靶向能力。Cur-P-NPs 可有效提高 Cur 的生物利用度,在药物递送和肿瘤管理方面具有潜在应用价值。